Across TCGA pan-cancer cohorts, TMED9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMED9 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher TMED9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMED9 expression acts as an unfavorable survival marker.

CESC, LUSC, and UCEC are the cancer types where TMED9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.053	0.823	<.001	42	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TMED9 tumor-vs-normal RNA expression · all TMED9 data types